Drug-induced progressive multifocal leukoencephalopathy in multiple sclerosis: European regulators' perspective.


Progressive multifocal leukoencephalopathy (PML) has been associated with the use of a number of multiple sclerosis (MS) immunomodulatory therapies and has assumed a critical place in the evaluation of their benefit/risk. In this review, we discuss the European Union regulatory approach to drug-induced PML in MS, highlight a number of key issues related to… (More)
DOI: 10.1002/cpt.604


Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.